Phase <scp>I</scp>/<scp>II</scp> trial assessing bendamustine plus bortezomib combination therapy for the treatment of patients with relapsed or refractory multiple myelomaJames R. Berenson, Debra Mayo, Ori Yellin et al.|British Journal of Haematology|2012Cited by 53
International multicenter study comparing COVID-19 in patients with cancer to patients without cancer: Impact of risk factors and treatment modalities on survivorshipIssam Raad, Dimitrios P. Kontoyiannis, Bilal Siddiqui et al.|eLife|2023Cited by 18
372. Comparing the Outcome of COVID-19 in Cancer and Non-Cancer Patients: an International Multicenter StudyRay Hachem, Tarcila Santos Datoguia, Bilal Siddiqui et al.|Open Forum Infectious Diseases|2020Cited by 7
Bendamustine Combined with Bortezomib Has Efficacy in Patients with Relapsed or Refractory Multiple Myeloma: A Phase 1/2 StudyJames R. Berenson, Debra Mayo, Ori Yellin et al.|Blood|2011Cited by 6